Ernexa Therapeutics Inc.
corporate_fare Company Profile
Ernexa Therapeutics Inc. (NASDAQ:ERNA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for ERNA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ERNA spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Ernexa Q3 2026: $5.6M Cash, Going-Concern Warning, $12.5M Nine-Month Loss
- Ernexa's ERNA-101 Clears Key Safety Hurdles, IND Filing Set for Q4
- Ernexa's ERNA-201 Shows Disease-Modifying Activity in Arthritis Model, Paving Way for ERNA-101 IND
- Ernexa Q2 2026: Cash Drops to $5M, Going Concern Relies on ATM Sales; Nasdaq Compliance Regained but Under Monitor
- Independent Study Shows ERNA-101 Combo Clears Tumors in 67% of Ovarian Cancer Models
Financial Snapshot
Short Interest & Short Volume
2.03 days to coverFINRA reported short interest of 33,263 shares in ERNA as of the October 30, 2026 settlement, a 67.3% increase from the prior period — about 2.0 days to cover at its recent average daily volume. On November 20, 2026, 25.0% of ERNA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.